{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T05:20:20Z","timestamp":1740720020293,"version":"3.38.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T00:00:00Z","timestamp":1737590400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100020218","name":"Chiesi USA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s12325-024-03095-2","type":"journal-article","created":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T07:19:45Z","timestamp":1737616785000},"page":"1421-1434","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health State Utility Values in Fabry Disease: Insights from the Pegunigalsidase Alfa Clinical Trials"],"prefix":"10.1007","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct03018730","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02795676","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03180840","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9226-0544","authenticated-orcid":false,"given":"Khashayar","family":"Azimpour","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Dorling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Koulinska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swati","family":"Kunduri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Poritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angie","family":"Raad-Faherty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,23]]},"reference":[{"issue":"1\u20132","key":"3095_CR1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.ymgme.2022.07.010","volume":"137","author":"DP Germain","year":"2022","unstructured":"Germain DP, Altarescu G, Barriales-Villa R, et al. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease. Mol Genet Metab. 2022;137(1\u20132):49\u201361. https:\/\/doi.org\/10.1016\/j.ymgme.2022.07.010.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3095_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbagen.2019.129437","volume":"1864","author":"JJ Miller","year":"2020","unstructured":"Miller JJ, Kanack AJ, Dahms NM. Progress in the understanding and treatment of Fabry disease. Biochim Biophys Acta Gen Subj. 2020;1864(1): 129437. https:\/\/doi.org\/10.1016\/j.bbagen.2019.129437.","journal-title":"Biochim Biophys Acta Gen Subj"},{"issue":"4","key":"3095_CR3","doi-asserted-by":"publisher","first-page":"569","DOI":"10.2215\/CJN.09480819","volume":"15","author":"E Svarstad","year":"2020","unstructured":"Svarstad E, Marti HP. The changing landscape of Fabry disease. Clin J Am Soc Nephrol. 2020;15(4):569\u201376. https:\/\/doi.org\/10.2215\/CJN.09480819.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3095_CR4","unstructured":"Mehta A, Hughes DA. Fabry disease. In: Adam MP, Mirzaa GM, Pagon RA, et al., editors. GeneReviews(\u00ae). Seattle (WA): University of Washington, Seattle; 2023."},{"issue":"3","key":"3095_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.107692","volume":"140","author":"Y Winter","year":"2023","unstructured":"Winter Y, Hilz M, Beuschlein F, et al. Screening for health-related quality of life and its determinants in Fabry disease: a cross-sectional multicenter study. Mol Genet Metab. 2023;140(3):107692. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107692.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3095_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-024-03131-y","volume":"19","author":"A Jovanovic","year":"2024","unstructured":"Jovanovic A, Miller-Hodges E, Castriota F, Takyar S, Howitt H, Ayodele O. A systematic literature review on the health-related quality of life and economic burden of Fabry disease. Orphanet J Rare Dis. 2024;19(1):181. https:\/\/doi.org\/10.1186\/s13023-024-03131-y.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"3095_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s10545-017-0095-6","volume":"41","author":"M Arends","year":"2018","unstructured":"Arends M, Korver S, Hughes DA, Mehta A, Hollak CEM, Biegstraaten M. Phenotype, disease severity and pain are major determinants of quality of life in Fabry disease: results from a large multicenter cohort study. J Inherit Metab Dis. 2018;41(1):141\u20139. https:\/\/doi.org\/10.1007\/s10545-017-0095-6.","journal-title":"J Inherit Metab Dis"},{"key":"3095_CR8","doi-asserted-by":"publisher","DOI":"10.36469\/jheor.2023.71344","author":"D Hughes","year":"2023","unstructured":"Hughes D, Lenny A, Shah K, Longworth L, Devercelli G, Ayodele O. Estimation of health state utility values in Fabry disease using vignette development and valuation. J Health Econ Outcomes Res. 2023. https:\/\/doi.org\/10.36469\/jheor.2023.71344.","journal-title":"J Health Econ Outcomes Res"},{"issue":"3","key":"3095_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2019.01.004","volume":"22","author":"J Brazier","year":"2019","unstructured":"Brazier J, Ara R, Azzabi I, et al. Identification, review, and use of health state utilities in cost-effectiveness models: an ISPOR good practices for outcomes research task force report. Value Health. 2019;22(3):267\u201375. https:\/\/doi.org\/10.1016\/j.jval.2019.01.004.","journal-title":"Value Health"},{"issue":"6","key":"3095_CR10","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/0021-9681(87)90019-1","volume":"40","author":"GW Torrance","year":"1987","unstructured":"Torrance GW. Utility approach to measuring health-related quality of life. J Chronic Dis. 1987;40(6):593\u2013600. https:\/\/doi.org\/10.1016\/0021-9681(87)90019-1.","journal-title":"J Chronic Dis"},{"issue":"6","key":"3095_CR11","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s10198-021-01411-z","volume":"23","author":"A Wang","year":"2022","unstructured":"Wang A, Rand K, Yang Z, Brooks R, Busschbach J. The remarkably frequent use of EQ-5D in non-economic research. Eur J Health Econ. 2022;23(6):1007\u201314. https:\/\/doi.org\/10.1007\/s10198-021-01411-z.","journal-title":"Eur J Health Econ"},{"issue":"6","key":"3095_CR12","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40273-020-00893-8","volume":"38","author":"AJ Thompson","year":"2020","unstructured":"Thompson AJ, Turner AJ. A comparison of the EQ-5D-3L and EQ-5D-5L. Pharmacoeconomics. 2020;38(6):575\u201391. https:\/\/doi.org\/10.1007\/s40273-020-00893-8.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"3095_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40273-022-01218-7","volume":"41","author":"M Hern\u00e1ndez Alava","year":"2023","unstructured":"Hern\u00e1ndez Alava M, Pudney S, Wailoo A. Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from a UK population study. Pharmacoeconomics. 2023;41(2):199\u2013207. https:\/\/doi.org\/10.1007\/s40273-022-01218-7.","journal-title":"Pharmacoeconomics"},{"key":"3095_CR14","doi-asserted-by":"publisher","unstructured":"Hernandez-Alava M, Pudney S, Wailoo A. (2020) Estimating the relationship between EQ-5D-5L and EQ-5D-3L: results from an English population study (PDF, 1.3MB). Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. Report 063. https:\/\/doi.org\/10.15131\/shef.data.25219157.","DOI":"10.15131\/shef.data.25219157"},{"key":"3095_CR15","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1023\/A:1015009210639","volume":"11","author":"AH Miners","year":"2002","unstructured":"Miners AH, Holmes A, Sherr L, Jenkinson C, MacDermot KD. Assessment of health-related quality-of-life in males with Anderson Fabry disease before therapeutic intervention. Qual Life Res. 2002;11:127\u201333.","journal-title":"Qual Life Res"},{"issue":"3","key":"3095_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1136\/jmg.2004.025791","volume":"42","author":"B Hoffmann","year":"2005","unstructured":"Hoffmann B, Garcia de Lorenzo A, Mehta A, et al. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet. 2005;42(3):247\u201352. https:\/\/doi.org\/10.1136\/jmg.2004.025791.","journal-title":"J Med Genet"},{"issue":"6","key":"3095_CR17","doi-asserted-by":"publisher","first-page":"741","DOI":"10.2478\/s11536-011-0087-0","volume":"6","author":"W \u017buraw","year":"2011","unstructured":"\u017buraw W, Golicki D, Jurecka A, Tylki-Szyma\u0144ska A. Quality of life among polish Fabry patients \u2014 a cross-sectional study quality of life among polish Fabry patients. Open Med. 2011;6(6):741\u20139. https:\/\/doi.org\/10.2478\/s11536-011-0087-0.","journal-title":"Open Med"},{"key":"3095_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","volume":"10","author":"M Arends","year":"2015","unstructured":"Arends M, Hollak CE, Biegstraaten M. Quality of life in patients with Fabry disease: a systematic review of the literature. Orphanet J Rare Dis. 2015;10:77. https:\/\/doi.org\/10.1186\/s13023-015-0296-8.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"3095_CR19","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/j.cgh.2007.08.012","volume":"5","author":"B Hoffmann","year":"2007","unstructured":"Hoffmann B, Schwarz M, Mehta A, Keshav S, Fabry Outcome Survey European I. Gastrointestinal symptoms in 342 patients with Fabry disease: prevalence and response to enzyme replacement therapy. Clin Gastroenterol Hepatol. 2007;5(12):1447\u201353. https:\/\/doi.org\/10.1016\/j.cgh.2007.08.012.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"3095_CR20","doi-asserted-by":"publisher","first-page":"80","DOI":"10.36469\/001c.71344","volume":"10","author":"D Hughes","year":"2023","unstructured":"Hughes D, Lenny A, Shah K, Longworth L, Devercelli G, Ayodele O. Estimation of health state utility values in fabry disease using vignette development and valuation. J Health Econ Outcomes Res. 2023;10(1):80\u20138. https:\/\/doi.org\/10.36469\/001c.71344.","journal-title":"J Health Econ Outcomes Res"},{"issue":"6","key":"3095_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s40265-021-01486-1","volume":"81","author":"M Lenders","year":"2021","unstructured":"Lenders M, Brand E. Fabry disease: the current treatment landscape. Drugs. 2021;81(6):635\u201345. https:\/\/doi.org\/10.1007\/s40265-021-01486-1.","journal-title":"Drugs"},{"issue":"4","key":"3095_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab. 2018;123(4):416\u201327. https:\/\/doi.org\/10.1016\/j.ymgme.2018.02.014.","journal-title":"Mol Genet Metab"},{"key":"3095_CR23","unstructured":"EMA. Replagal (agalsidase alfa) is authorised for use in the European Union. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/replagal. 2001. Accessed 30 Aug 2023."},{"key":"3095_CR24","unstructured":"Health Canada. Replagal (agalsidase alfa) approved; issued Notice of Compliance in accordance with the Food and Drug Regulations. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00217 2017. Accessed 13 Nov 2023."},{"key":"3095_CR25","unstructured":"PMDA. Replagal (agalsidase alfa) is approved by Pharmaceuticals and Medicals Devices Agency (PMDA) of Japan. https:\/\/www.pmda.go.jp\/files\/000267893.pdf. 2006. Accessed 30 Aug 2023."},{"key":"3095_CR26","unstructured":"Therapeutic Goods Administration. Replagal (agalsidase alfa) approval: Australian product information. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-replagal.pdf. 2010. Accessed 30 Jul 2024."},{"key":"3095_CR27","unstructured":"FDA. Fabrazyme (agalsidase beta) approved in the US. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/detailedIndex.cfm?cfgridkey=15286. 2023. Accessed 30 Aug 2023."},{"key":"3095_CR28","unstructured":"EMA. Fabrazyme (agalsidase beta) is authorised for use in the European Union. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/fabrazyme#authorisation-details-section. 2001. Accessed 30 Aug 2023."},{"key":"3095_CR29","unstructured":"Health Canada. Fabrazyme (agalsidase beta) is approved by Health Canada. https:\/\/health-products.canada.ca\/dpd-bdpp\/info?lang=eng&code=73340. 2004. Accessed 30 Aug 2023."},{"key":"3095_CR30","unstructured":"PMDA. Fabrazyme (agalsidase beta) is approved by Pharmaceuticals and Medicals Devices Agency (PMDA) of Japan. https:\/\/www.pmda.go.jp\/files\/000241924.pdf. 2004. Accessed 30 Aug 2023."},{"key":"3095_CR31","unstructured":"Therapeutic Goods Administration. Fabrazyme (agalsidase beta) approval: Australian product information. https:\/\/www.tga.gov.au\/resources\/artg\/94000. 2004. Accessed 30 Jul 2024."},{"key":"3095_CR32","unstructured":"FDA. Approved Elfabrio (pegunigalsidase alfa-iwxj) injection, for intravenous use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2023\/761161Orig1s000ltr.pdf. 2023. Accessed 30 Aug 2023."},{"key":"3095_CR33","unstructured":"EMA. Elfabrio (pegunigalsidase alfa) is authorised for use in the European Union. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/elfabrio#authorisation-details-section. 2023. Accessed 30 Aug 2023."},{"key":"3095_CR34","unstructured":"FDA. Galafold (migalastat) is approved in the US. https:\/\/www.fda.gov\/drugs\/novel-drug-approvals-fda\/novel-drug-approvals-2018. 2018. Accessed 30 Aug 2023."},{"key":"3095_CR35","unstructured":"EMA. Galafold (migalastat) is authorised for use in the European Union. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/galafold. 2023. Accessed 30 Aug 2023."},{"key":"3095_CR36","unstructured":"Health Canada. Galafold (migalastat hydrochloride) Approved; issued a Notice of Compliance in accordance with the Food and Drug Regulations. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/RDS00291. 2017. Accessed 13 Nov 2023."},{"key":"3095_CR37","unstructured":"PDMA. Galafold (migalastat hydrochloride) is approved by Pharmaceuticals and Medicals Devices Agency (PMDA) of Japan. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0001.html. 2018. Accessed 30 Jul 2024."},{"key":"3095_CR38","unstructured":"Therapeutic Goods Administration. Galafold (migalastat) approval: Australian product information. https:\/\/www.tga.gov.au\/sites\/default\/files\/auspar-migalastat-180830-pi.pdf. 2018. Accessed 30 Jul 2024."},{"issue":"6","key":"3095_CR39","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1136\/jmg-2023-109445","volume":"61","author":"EL Wallace","year":"2024","unstructured":"Wallace EL, Goker-Alpan O, Wilcox WR, et al. Head-to-head trial of pegunigalsidase alfa versus agalsidase beta in patients with Fabry disease and deteriorating renal function: results from the 2-year randomised phase\u00a0III BALANCE study. J Med Genet. 2024;61(6):520\u201330. https:\/\/doi.org\/10.1136\/jmg-2023-109445.","journal-title":"J Med Genet"},{"issue":"1","key":"3095_CR40","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s13023-023-02937-6","volume":"18","author":"A Linhart","year":"2023","unstructured":"Linhart A, Dostalova G, Nicholls K, et al. Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase\u00a03 open-label study. Orphanet J Rare Dis. 2023;18(1):332. https:\/\/doi.org\/10.1186\/s13023-023-02937-6.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"3095_CR41","doi-asserted-by":"publisher","first-page":"S91","DOI":"10.1016\/j.gim.2022.01.185","volume":"24","author":"J Bernat","year":"2022","unstructured":"Bernat J, Holida M, Longo N, et al. eP149: Safety and efficacy of pegunigalsidase alfa, every 4\u00a0weeks, in Fabry disease: results from the phase\u00a03, open-label BRIGHT study. Genet Med. 2022;24(3):S91\u20132. https:\/\/doi.org\/10.1016\/j.gim.2022.01.185.","journal-title":"Genet Med"},{"key":"3095_CR42","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jhealeco.2017.06.013","volume":"55","author":"M Hern\u00e1ndez-Alava","year":"2017","unstructured":"Hern\u00e1ndez-Alava M, Pudney S. Econometric modelling of multiple self-reports of health states: the switch from EQ-5D-3L to EQ-5D-5L in evaluating drug therapies for rheumatoid arthritis. J Health Econ. 2017;55:139\u201352. https:\/\/doi.org\/10.1016\/j.jhealeco.2017.06.013.","journal-title":"J Health Econ"},{"issue":"5","key":"3095_CR43","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"3095_CR44","unstructured":"NICE. Position Statement on Use of the EQ-5D-5L Value Set for England. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/technology-appraisal-guidance\/eq-5d-5l. Updated Oct 2019. 2019."},{"issue":"1","key":"3095_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12962-022-00369-w","volume":"20","author":"EI Katsigianni","year":"2022","unstructured":"Katsigianni EI, Petrou P. A systematic review of economic evaluations of enzyme replacement therapy in lysosomal storage diseases. Cost Eff Resour Alloc. 2022;20(1):51. https:\/\/doi.org\/10.1186\/s12962-022-00369-w.","journal-title":"Cost Eff Resour Alloc"},{"key":"3095_CR46","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1750-1172-8-29","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Hollak CE, Linthorst GE, Dijkgraaf MG. Cost-effectiveness of enzyme replacement therapy for Fabry disease. Orphanet J Rare Dis. 2013;8:29. https:\/\/doi.org\/10.1186\/1750-1172-8-29.","journal-title":"Orphanet J Rare Dis"},{"issue":"1\u20132","key":"3095_CR47","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ymgme.2016.06.007","volume":"119","author":"RJ Hopkin","year":"2016","unstructured":"Hopkin RJ, Cabrera G, Charrow J, et al. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: data from the Fabry Registry. Mol Genet Metab. 2016;119(1\u20132):151\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2016.06.007.","journal-title":"Mol Genet Metab"},{"key":"3095_CR48","unstructured":"Papaioannou D, Brazier J, Paisely S. NICE DSU Technical Support Document 9: The Identification, Review, and Synthesis of Health State Utility Values From the Literature. Report by the Decision Support Unit. 2010."},{"issue":"7299","key":"3095_CR49","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1136\/bmj.322.7299.1417","volume":"322","author":"J Addington-Hall","year":"2001","unstructured":"Addington-Hall J, Kalra L. Who should measure quality of life? BMJ. 2001;322(7299):1417\u201320. https:\/\/doi.org\/10.1136\/bmj.322.7299.1417.","journal-title":"BMJ"},{"key":"3095_CR50","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/02729890122062488","volume":"21","author":"PA Ubel","year":"2001","unstructured":"Ubel PA, Loewenstein G, Hershey J, et al. Do nonpatients underestimate the quality of life associated with crhonic health conditions because of a focusing illusion? Med Decis Mak. 2001;21:190\u20139.","journal-title":"Med Decis Mak"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03095-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-03095-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-03095-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T08:38:36Z","timestamp":1740645516000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-03095-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,23]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3095"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-03095-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"type":"print","value":"0741-238X"},{"type":"electronic","value":"1865-8652"}],"subject":[],"published":{"date-parts":[[2025,1,23]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Khashayar Azimpour, Patricia Dorling, Irene Koulinska, and Swati Kunduri are employees of Chiesi. Zhiyi Lan, Julia Poritz, Gabriel Tremblay, and Angie Raad-Faherty are employees of Cytel Inc.; Chiesi commissioned Cytel Inc. for the study design, analysis, and development of the manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data in this article is not identifiable; therefore, ethics committee approval was not required for this study. For the BALANCE, BRIDGE, and BRIGHT studies, an institutional review board or independent ethics committee reviewed and approved the study protocol and any amendments prior to their implementation, each study was conducted in accordance with the Declaration of Helsinki, in compliance with the approved protocol, Good Clinical Practice guidelines, and applicable regulatory requirements. Written informed consent was obtained from all study participants of the BALANCE, BRIDGE, and BRIGHT studies that included permission to use study data in future analyses. Data from the BALANCE, BRIDGE, and BRIGHT studies was obtained and accessed via Chiesi Farmaceutici S.p.A. who are owners of the data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}